Daniel is a partner in Kirkland’s IP litigation team in London. Daniel has a broad practice which covers a wide range of technical fields, but is particularly noted for his expertise in life sciences patent litigation, particularly in the pharmaceutical industry, diagnostics and the emerging fields of precision medicine and cell and gene therapy. He is also experienced in representing clients involved in complex Standard Essential Patent and FRAND licensing disputes.
In addition to UK litigation, Daniel is regularly called upon to assist clients in devising, coordinating and executing patent strategies for complex multijurisdictional disputes at a pan-European and global scale. With dual qualifications in law and biochemistry, and experience litigating in multiple jurisdictions around the world, Daniel is readily able to grasp highly technical material and the international dimensions of disputes which are often at the heart of effective strategies in blockbuster litigation for the most sophisticated clients.
Daniel is recognised as a thought leader and regular writer, speaker and commentator on a wide range of topics relating to the life sciences industry and IP generally, notably including the rising gene editing technology CRISPR. Testament to his standing and leadership in the IP community, Daniel currently serves as the Vice-Chair of two standing committees of the International Association for the Protection of Intellectual Property (AIPPI): the Biotechnology committee as well as the committee on IP and Genetic Resources and Traditional Knowledge.
Daniel has recently been described in IAM Patent 1000 as a “Life sciences genius with the ability to quickly unpick the most arcane biochemistry issues”